Cargando…
A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs in cattle and costs US agriculture a billion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the host response to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830518/ https://www.ncbi.nlm.nih.gov/pubmed/27073858 http://dx.doi.org/10.1371/journal.pone.0152913 |
_version_ | 1782426905057689600 |
---|---|
author | Walsh, Paul Behrens, Nicole Carvallo Chaigneau, Francisco R. McEligot, Heather Agrawal, Karan Newman, John W. Anderson, Mark Gershwin, Laurel J. |
author_facet | Walsh, Paul Behrens, Nicole Carvallo Chaigneau, Francisco R. McEligot, Heather Agrawal, Karan Newman, John W. Anderson, Mark Gershwin, Laurel J. |
author_sort | Walsh, Paul |
collection | PubMed |
description | BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs in cattle and costs US agriculture a billion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the host response to the virus. RSV is accompanied by elevated prostaglandin E(2) (PGE(2)) which is followed by neutrophil led inflammation in the lung. Ibuprofen is a prototypical non-steroidal anti-inflammatory drug that decreases PGE(2) levels by inhibiting cyclooxygenase. HYPOTHESES: We hypothesized that treatment of RSV with ibuprofen would decrease PGE(2) levels, modulate the immune response, decrease clinical illness, and decrease the histopathological lung changes in a bovine model of RSV. We further hypothesized that viral replication would be unaffected. METHODS: We performed a randomized placebo controlled trial of ibuprofen in 16 outbred Holstein calves that we infected with RSV. We measured clinical scores, cyclooxygenase, lipoxygenase and endocannabinoid products in plasma and mediastinal lymph nodes and interleukin (Il)-4, Il-13, Il-17 and interferon-γ in mediastinal lymph nodes. RSV shedding was measured daily and nasal Il-6, Il-8 and Il-17 every other day. The calves were necropsied on Day 10 post inoculation and histology performed. RESULTS: One calf in the ibuprofen group required euthanasia on Day 8 of infection for respiratory distress. Clinical scores (p<0.01) and weight gain (p = 0.08) seemed better in the ibuprofen group. Ibuprofen decreased cyclooxygenase, lipoxygenase, and cytochrome P450 products, and increased monoacylglycerols in lung lymph nodes. Ibuprofen modulated the immune response as measured by narrowed range of observed Il-13, Il-17 and IFN-γ gene expression in mediastinal lymph nodes. Lung histology was not different between groups, and viral shedding was increased in calves randomized to ibuprofen. CONCLUSIONS: Ibuprofen decreased PGE(2), modulated the immune response, and improved clinical outcomes. However lung histopathology was not affected and viral shedding was increased. |
format | Online Article Text |
id | pubmed-4830518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-48305182016-04-22 A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model Walsh, Paul Behrens, Nicole Carvallo Chaigneau, Francisco R. McEligot, Heather Agrawal, Karan Newman, John W. Anderson, Mark Gershwin, Laurel J. PLoS One Research Article BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital admission in infants. An analogous disease occurs in cattle and costs US agriculture a billion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the host response to the virus. RSV is accompanied by elevated prostaglandin E(2) (PGE(2)) which is followed by neutrophil led inflammation in the lung. Ibuprofen is a prototypical non-steroidal anti-inflammatory drug that decreases PGE(2) levels by inhibiting cyclooxygenase. HYPOTHESES: We hypothesized that treatment of RSV with ibuprofen would decrease PGE(2) levels, modulate the immune response, decrease clinical illness, and decrease the histopathological lung changes in a bovine model of RSV. We further hypothesized that viral replication would be unaffected. METHODS: We performed a randomized placebo controlled trial of ibuprofen in 16 outbred Holstein calves that we infected with RSV. We measured clinical scores, cyclooxygenase, lipoxygenase and endocannabinoid products in plasma and mediastinal lymph nodes and interleukin (Il)-4, Il-13, Il-17 and interferon-γ in mediastinal lymph nodes. RSV shedding was measured daily and nasal Il-6, Il-8 and Il-17 every other day. The calves were necropsied on Day 10 post inoculation and histology performed. RESULTS: One calf in the ibuprofen group required euthanasia on Day 8 of infection for respiratory distress. Clinical scores (p<0.01) and weight gain (p = 0.08) seemed better in the ibuprofen group. Ibuprofen decreased cyclooxygenase, lipoxygenase, and cytochrome P450 products, and increased monoacylglycerols in lung lymph nodes. Ibuprofen modulated the immune response as measured by narrowed range of observed Il-13, Il-17 and IFN-γ gene expression in mediastinal lymph nodes. Lung histology was not different between groups, and viral shedding was increased in calves randomized to ibuprofen. CONCLUSIONS: Ibuprofen decreased PGE(2), modulated the immune response, and improved clinical outcomes. However lung histopathology was not affected and viral shedding was increased. Public Library of Science 2016-04-13 /pmc/articles/PMC4830518/ /pubmed/27073858 http://dx.doi.org/10.1371/journal.pone.0152913 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Walsh, Paul Behrens, Nicole Carvallo Chaigneau, Francisco R. McEligot, Heather Agrawal, Karan Newman, John W. Anderson, Mark Gershwin, Laurel J. A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model |
title | A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model |
title_full | A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model |
title_fullStr | A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model |
title_full_unstemmed | A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model |
title_short | A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model |
title_sort | randomized placebo controlled trial of ibuprofen for respiratory syncytial virus infection in a bovine model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830518/ https://www.ncbi.nlm.nih.gov/pubmed/27073858 http://dx.doi.org/10.1371/journal.pone.0152913 |
work_keys_str_mv | AT walshpaul arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT behrensnicole arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT carvallochaigneaufranciscor arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT mceligotheather arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT agrawalkaran arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT newmanjohnw arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT andersonmark arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT gershwinlaurelj arandomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT walshpaul randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT behrensnicole randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT carvallochaigneaufranciscor randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT mceligotheather randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT agrawalkaran randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT newmanjohnw randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT andersonmark randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel AT gershwinlaurelj randomizedplacebocontrolledtrialofibuprofenforrespiratorysyncytialvirusinfectioninabovinemodel |